Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Turkish Version of Telehealth Usability Questionnaire (TUQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04802512
Recruitment Status : Recruiting
First Posted : March 17, 2021
Last Update Posted : March 18, 2021
Sponsor:
Information provided by (Responsible Party):
Irem Hüzmeli, Mustafa Kemal University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The Telehealth Usability Questionnaire (TUQ) was developed to evaluate the usability of telehealth applications and services. The Turkish validity and reliability study of the scale, originally in English, has not been conducted before.

The aim of this study is to develop the Turkish version of the Telehealth Usability Questionnaire (TUQ), which is a new stability tool, and to report its reliability assessment.


Condition or disease Intervention/treatment
Health Care Acceptor Health Knowledge, Attitudes, Practice Patient Participation Procedure: validity and reability study

Detailed Description:
The Telehealth Usability Questionnaire (TUQ) turkish version will be asked by using google forms to participants whom use telehealth.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 170 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 15 Days
Official Title: Investigation of the Turkish Validity and Reliability of the Telehealth Usability Questionnaire (TUQ)
Actual Study Start Date : March 12, 2021
Estimated Primary Completion Date : June 12, 2022
Estimated Study Completion Date : June 12, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Telehealth

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
patients
patients who were used telehealth
 Procedure: validity and reability study
validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)
health professional
health professional who were used telehealth.
 Procedure: validity and reability study
validity and reliability assessment of the Turkish version of the Telehealth Usability Questionnaire (TUQ)


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Reliability and Validity of TUQ by Correlation Analysis. [ Time Frame: 12 month ]
    with telehealth will be researched


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The Turkish validity and reliability of the scale, which was created to evaluate the usability of the telehealth service for service users (patients) and providers (health professional), will be investigated.
Criteria

Inclusion Criteria:

Participants will undergo screening to confirm eligibility, completion of initial screening form, and MMSE evaluation. Study subjects were enrolled with MMSE scores between 29-30, inclusive (healthy/control), 25-28, inclusive (mild cognitive impairment), and 10-24 (dementia).

-

Exclusion Criteria:

  • Unable to complete computerized and standard pencil-and-paper based assessments
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04802512


Contacts
Layout table for location contacts
Contact: Irem huzmeli, Phd +90326221 33 17 fztirem@gmail.com
Contact: Esra Dogru huzmeli, Assoc. prof. +90326221 33 17 edogru001@hotmail.com

Locations
Layout table for location information
Turkey
Hatay Mustafa Kemal University Not yet recruiting
Hatay, Merkez, Turkey, 31010
Contact: Irem Hüzmeli, PHD    +90 (326) 221 33 17 ext 15550    fztirem@gmail.com   
Sub-Investigator: Irem Hüzmeli, PhD         
Principal Investigator: Esra Dogru Huzmeli, PhD         
Sub-Investigator: Mehmet Karadag, PhD         
Online Recruiting
Hatay, Turkey
Contact: irem huzmeli, phd    +903262213317    fztirem@gmail.com   
Sponsors and Collaborators
Irem Hüzmeli
Investigators
Layout table for investigator information
Study Director: Irem Huzmeli, Phd Mustafa Kemal University
Principal Investigator: Esra Dogru Huzmeli, Assoc Prof. Mustafa Kemal University
Study Chair: Mehmet Karadağ, Asist. Prof. Mustafa Kemal University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Irem Hüzmeli, Phd lecturer, Mustafa Kemal University
ClinicalTrials.gov Identifier: NCT04802512    
Other Study ID Numbers: HatayMustafaKU
First Posted: March 17, 2021    Key Record Dates
Last Update Posted: March 18, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No